A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).

被引：0

作者：

Loriot, Yohann

Siefker-Radtke, Arlene O.

Friedlander, Terence W.

Necchi, Andrea

Wei, Alexander Z.

Sridhar, Srikala S.

Garmezy, Benjamin

Arroyo, Santiago

Gartside, Emma

Liu, Jie

Campbell, Carly

Bader, Justin

Petrylak, Daniel P.

机构：

[1] Univ Paris Saclay, Gustave Roussy Inst, Villejuif, France

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[4] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Milan, Italy

[5] Columbia Univ, Med Ctr, Dept Med, New York, NY USA

[6] Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] Sarah Cannon Res Inst, Nashville, TN USA

[8] Bicycle Therapeut, Cambridge, MA USA

[9] BicycleTx Ltd, Cambridge, England

[10] Yale Sch Med, New Haven, CT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.5_suppl.TPS898

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS898 / TPS898

页数：1

共 50 条

[41] evERA Breast Cancer (BC): Phase III study of giredestrant plus everolimus vs exemestane plus everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2-LA/mBC)
Mayer, Erica L.
Tolaney, Sara M.
Brufsky, Adam
Gradishar, William John
Jhaveri, Komal L.
Martin, Miguel
Moscetti, Luca
Schneeweiss, Andreas
Vidal, Gregory A.
Cortazar, Patricia
Feldman, Merilin
Day, Bann-mo
Rugo, Hope S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[42] Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer
Janku, Filip
Juric, Dejan
Cortes, Javier
Rugo, Hope
Burris, Howard A.
Schuler, Martin
Deschler-Baier, Barbara
Middleton, Mark R.
Gil-Martin, Marta
Berlin, Jordan
Winer, Eric
Bootle, Douglas
Blumenstein, Lars
Demanse, David
Coughlin, Christina
Quadt, Cornelia
Baselga, Jose
CANCER RESEARCH, 2015, 75
[43] INAVO121: Phase III study of inavolisib plus fulvestrant vs alpelisib plus fulvestrant in patients with hormone receptorpositive, HER2-negative, PIK3CAmutated locally advanced or metastatic breast cancer
Juric, Dejan
Kalinsky, Kevin
Im, Seock-Ah
Ciruelos, Eva
Bianchini, Giampaolo
Barrios, Carlos
Jacot, William
Schmid, Peter
Loi, Sherene
Rugo, Hope
Craine, Veronica
Hutchinson, Katherine
Flechais, Aulde
Thanopoulou, Eirini
Harbeck, Nadia
CANCER RESEARCH, 2024, 84 (09)
[44] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
Turner, Nicolas
Jhaveri, Komal
Kalinsky, Kevin
Loibl, Sibylle
Loi, Sherene
Im, Seock-Ah
Saura, Cristina
Schmid, Peter
Schutzman, Jennifer L.
Stout, Thomas J.
Lei, Guiyuan
Hutchinson, Katherine E.
Thanopoulou, Eirini
Juric, Dejan
CANCER RESEARCH, 2021, 81 (04)
[45] Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma.
Sheng, Xinan
Zhou, Li
He, Zhisong
Guo, Hongqian
Yan, Xieqiao
Li, Siming
Xu, Huayan
Li, Juan
Chi, Zhihong
Si, Lu
Cui, Chuanliang
Mao, Lili
Lian, Bin
Tang, Bixia
Wang, Xuan
Bai, Xue
Guo, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[46] BL-M07D1, an antibody- drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study
Song, Erwei
Yao, Herui
Sun, Meili
Zong, Hong
Lin, Rongbo
Zou, Wen
Ding, Muran
Yu, Jing
Xiao, Sa
Wang, Hongwei
Zhu, Hai
Olivo, Martin
Zhu, Yi
CANCER RESEARCH, 2024, 84 (09)
[47] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
Turner, N.
Jhaveri, K.
Kalinsky, K.
Loibl, S.
Loi, S.
Im, S-A.
Saura, C.
Schmid, P.
Schutzman, J. L.
Stout, T.
Lei, G.
Hutchinson, K. E.
Thanopoulou, E.
Juric, D.
ANNALS OF ONCOLOGY, 2020, 31 : S391 - S392
[48] Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2-LA/mBC)
Turner, Nicolas C.
Loi, Sherene
Moore, Heather M.
Chang, Ching-Wei
Eng-Wong, Jennifer
Bardia, Aditya
Boni, Valentina
Sohn, Joohyuk
Jhaveri, Komal L.
Lim, Elgene
CANCER RESEARCH, 2022, 82 (04)
[49] Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).
Jhaveri, Komal L.
Boni, Valentina
Sohn, Joohyuk
Villanueva-Vasquez, Rafael
Bardia, Aditya
Schmid, Peter
Lim, Elgene
Patel, Jaymin M.
Alejandro Perez-Fidalgo, Jose
Loi, Sherene
Im, Seock-Ah
Kshirsagar, Smita
Gates, Mary R.
Bond, John
Eng-Wong, Jennifer
Chang, Ching-Wei
Turner, Nicholas C.
Lopez Miranda, Elena
Garcia-Estevez, Laura
Bellet, Meritxell
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[50] A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC)
Kang, Yoon-Koo
Shah, Manish A.
Ohtsu, Atsushi
Van Cutsem, Eric
Ajani, Jaffer A.
van der Horst, Tina
Harle-Yge, Marie-Laurence
Piao, Yongzhe
Althaus, Betsy
Thuss-Patience, Peter C.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)

← 1 2 3 4 5 →